{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:30:09Z","timestamp":1790191809738,"version":"4.1.0"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bioorg.2026.109609","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:21:35Z","timestamp":1770682895000},"page":"109609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The Multi-Faceted Landscape of TEAD Inhibition: a 2017\u20132025 Patent and Literature Review"],"prefix":"10.1016","volume":"173","author":[{"given":"Violet Yijang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Zhavoronkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bioorg.2026.109609_bb0005","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1101\/gad.888601","article-title":"TEAD\/TEF transcription factors utilize the activation domain of YAP65, a Src\/Yes-associated protein localized in the cytoplasm","volume":"15","author":"Vassilev","year":"2001","journal-title":"Genes Dev."},{"issue":"14","key":"10.1016\/j.bioorg.2026.109609_bb0010","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1101\/gad.1664408","article-title":"TEAD mediates YAP-dependent gene induction and growth control","volume":"22","author":"Zhao","year":"2008","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109609_bb0015","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","article-title":"The Hippo pathway and human cancer","volume":"13","author":"Harvey","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109609_bb0020","doi-asserted-by":"crossref","unstructured":"Piccolo, S., Panciera, T., Contessotto, P. et al. YAP\/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nat Cancer 4, 9\u201326 (2023). doi:https:\/\/doi.org\/10.1038\/s43018-022-00473-z.","DOI":"10.1038\/s43018-022-00473-z"},{"key":"10.1016\/j.bioorg.2026.109609_bb0025","doi-asserted-by":"crossref","unstructured":"Liu-Chittenden, Y., et al. (2012). Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev., 26(12), 1300\u20131305.","DOI":"10.1101\/gad.192856.112"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109609_bb0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.21037\/tlcr.2017.06.02","article-title":"Drug development against the hippo pathway in mesothelioma","volume":"6","year":"2017","journal-title":"Transl lung Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109609_bb0035","doi-asserted-by":"crossref","unstructured":"Trends Cancer. 2019 May;5(5):283-296. doi:https:\/\/doi.org\/10.1016\/j.trecan.2019.02.010. Epub 2019 Mar 27.","DOI":"10.1016\/j.trecan.2019.02.010"},{"key":"10.1016\/j.bioorg.2026.109609_bb0040","doi-asserted-by":"crossref","unstructured":"Nat Commun. 2018 Jul 9;9(1):2372. doi:https:\/\/doi.org\/10.1038\/s41467-018-04590-1.","DOI":"10.1038\/s41467-018-04590-1"},{"key":"10.1016\/j.bioorg.2026.109609_bb0045","doi-asserted-by":"crossref","unstructured":"J Cancer. 2020 Sep 25;11(22):6748-6759. doi:https:\/\/doi.org\/10.7150\/jca.48535. eCollection 2020.","DOI":"10.7150\/jca.48535"},{"key":"10.1016\/j.bioorg.2026.109609_bb0050","doi-asserted-by":"crossref","unstructured":"Cell. 2014 Jul 3;158(1):185-197. doi:https:\/\/doi.org\/10.1016\/j.cell.2014.06.003. Epub 2014 Jun 19.","DOI":"10.1016\/j.cell.2014.06.003"},{"key":"10.1016\/j.bioorg.2026.109609_bb0055","doi-asserted-by":"crossref","unstructured":"Park, H.W., et al. (2015). Alternative Wnt signaling activates YAP\/TAZ. Cell, 162(4), 780\u2013794.","DOI":"10.1016\/j.cell.2015.07.013"},{"key":"10.1016\/j.bioorg.2026.109609_bb0060","doi-asserted-by":"crossref","unstructured":"Structure. 2016 Jan 5;24(1):179-186. doi:https:\/\/doi.org\/10.1016\/j.str.2015.11.005. Epub 2015 Dec 24.","DOI":"10.1016\/j.str.2015.11.005"},{"key":"10.1016\/j.bioorg.2026.109609_bb0065","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.str.2015.09.009","article-title":"Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy","volume":"23","author":"Pobbati","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.bioorg.2026.109609_bb0070","doi-asserted-by":"crossref","unstructured":"a) Bum-Erdene, Khuchtumur et al. Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD\u22c5Yap Protein-Protein Interaction. Cell Chemical Biology, Volume 26, Issue 3, 378\u2013389.e13. b) University of Indiana. Compounds and methods to attenuate tumor progression and metastasis. WO2020087063A1; 2020.","DOI":"10.1016\/j.chembiol.2018.11.010"},{"key":"10.1016\/j.bioorg.2026.109609_bb0075","unstructured":"a) Woodard GA, Yang YL, You L and Jablons DM. Drug development against the Hippo pathway in mesothelioma. Transl Lung Cancer Res 2017; 6: 335-342. b) Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 2013; 34: 1413-1419. c) Kaneda A, et al. The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. Am J Cancer Res. 2020 Dec 1;10(12):4399-4415. PMID: 33415007; PMCID: PMC7783735."},{"key":"10.1016\/j.bioorg.2026.109609_rf0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111767","article-title":"Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors","volume":"184","author":"Lu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109609_or0055","unstructured":"Shanghai Institute of Materia Medica. Vinyl sulfonamide or vinyl amide compounds, and preparation method and application thereof. CN112010789A; 2019."},{"key":"10.1016\/j.bioorg.2026.109609_rf0035","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109609_rf0040","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1021\/acs.jmedchem.2c01548","article-title":"Structure-based design of Y-shaped covalent TEAD inhibitors","volume":"66","author":"Lu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109609_or0060","unstructured":"Note that there may be discrepancies in the protocol used for the TEAD-MCF7 reporter assay in the patents for compounds 30 and 98 (WO-2024019562 and WO-2024210578) compared to other patents that employ this assay."},{"key":"10.1016\/j.bioorg.2026.109609_rf0045","series-title":"Heterobicyclic compound and pharmaceutical composition comprising them","author":"Baobab AIBio","year":"2024"},{"key":"10.1016\/j.bioorg.2026.109609_rf0050","doi-asserted-by":"crossref","first-page":"18957","DOI":"10.1021\/acs.jmedchem.4c01393","article-title":"Pan-transcriptional enhanced associated domain palmitoylation pocket covalent inhibitor","volume":"67","author":"Kim","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109609_rf0055","series-title":"Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof","author":"Dana-Farber Cancer Institute","year":"2021"},{"key":"10.1016\/j.bioorg.2026.109609_rf0060","series-title":"Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof","author":"Dana-Farber Cancer Institute","year":"2020"},{"key":"10.1016\/j.bioorg.2026.109609_bb0100","series-title":"Small molecule inhibitors of tea domain family members","author":"The Scripps rResearch iInstitute","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_bb0105","series-title":"Polycyclic compound and use thereof","author":"Deuracor","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_bb0110","series-title":"\u03b1,\u03b2-Unsaturated amide compound and use thereof","author":"Signet Therapeutics","year":"2024"},{"key":"10.1016\/j.bioorg.2026.109609_bb0115","series-title":"Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof","author":"Dana-Farber Cancer Institute","year":"2021"},{"key":"10.1016\/j.bioorg.2026.109609_bb0120","series-title":"Compounds and methods for yap\/tead modulation and indications thereof","author":"Opna Immuno-Oncology","year":"2022"},{"key":"10.1016\/j.bioorg.2026.109609_bb0125","series-title":"(1H-indol-5-yl)acrylamide derivatives as inhibitors of tead proteins and the hippo-yap1\/taz signaling cascade for the treatment of cancer","author":"Sanofi","year":"2021"},{"key":"10.1016\/j.bioorg.2026.109609_bb0130","series-title":"Novel heterobicyclic compound for inhibiting YAP-TEAD interaction and pharmaceutical composition comprising them","author":"Hanmi Pharm","year":"2024"},{"key":"10.1016\/j.bioorg.2026.109609_bb0135","series-title":"Tead inhibitor, preparation method therefor. and medical use thereof","author":"JS Innomed Holdings","year":"2024"},{"key":"10.1016\/j.bioorg.2026.109609_bb0140","series-title":"Novel heterocyclic compound and pharmaceutical composition comprising them","author":"Samjin Pharmaceuticals","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_bb0145","series-title":"Therapeutic indazole compounds and methods of use in the treatment of cancer","author":"Genentech","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_bb0150","series-title":"Bicyclic compounds, compositions and use thereof","author":"Betta Pharmaceuticals","year":"2022"},{"key":"10.1016\/j.bioorg.2026.109609_bb0155","series-title":"Heterocyclic tead inhibitors","author":"Light Horse Therapeutics","year":"2024"},{"key":"10.1016\/j.bioorg.2026.109609_bb0160","series-title":"Acrylamide-substituted indane compounds and therapeutic use thereof","author":"Sanofi","year":"2022"},{"key":"10.1016\/j.bioorg.2026.109609_rf0130","series-title":"Bicyclic heteroaromatic compounds for treating cancer","author":"AstraZeneca","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_or0065","doi-asserted-by":"crossref","unstructured":"Jacob A. Gordon, et al; Abstract 6589: discovery of potent and selective pan-TEAD autopalmitoylation inhibitors for the treatment of hippo-pathway altered cancers. Cancer Res. 2024; 84 (6_Supplement): 6589. doi:https:\/\/doi.org\/10.1158\/1538-7445.AM2024-6589.","DOI":"10.1158\/1538-7445.AM2024-6589"},{"key":"10.1016\/j.bioorg.2026.109609_bb0170","series-title":"Bicyclic heteroaromatic compounds and their use in the treatment of cancer","author":"AstraZeneca","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_bb0175","series-title":"1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap\/taz-tead activation for treating cancer","author":"Springworks Therapeutics","year":"2022"},{"key":"10.1016\/j.bioorg.2026.109609_bb0180","series-title":"Tetrahydropyrazolopyrimidines and related analogs for inhibiting yap\/taz-tead","author":"Springworks Therapeutics","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_bb0185","series-title":"Novel aminobenzene derivative having cancer cell growth inhibitory effect, and preventive or therapeutic pharmaceutical composition containing same as active ingredient","author":"Daewoong","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_bb0190","series-title":"Novel benzoindolone compounds and pharmaceutical composition comprising them","author":"Samjin Pharmaceuticals","year":"2022"},{"key":"10.1016\/j.bioorg.2026.109609_bb0195","series-title":"Tead inhibitors and uses thereof","author":"Ikena Oncology","year":"2020"},{"key":"10.1016\/j.bioorg.2026.109609_bb0200","series-title":"Tead inhibitors and uses thereof","author":"Ikena Oncology","year":"2022"},{"key":"10.1016\/j.bioorg.2026.109609_bb0205","series-title":"Tead inhibitors and uses thereof","author":"Cedilla Therapeutics","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_bb0210","series-title":"2-pyrazole anilines and related analogs for inhibiting yap\/taz-tead","author":"Springworks Therapeutics","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_bb0215","series-title":"Therapeutic compounds and methods of use","author":"Genentech","year":"2021"},{"key":"10.1016\/j.bioorg.2026.109609_bb0220","series-title":"Heterocyclic inhibitors of tead for treating cancer","author":"Genentech","year":"2022"},{"key":"10.1016\/j.bioorg.2026.109609_bb0225","series-title":"Therapeutic compounds and methods of use","author":"Genentech","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_bb0230","series-title":"Tead transcription factor auto-palmitoylation inhibitors","author":"The General Hospital Corp","year":"2017"},{"key":"10.1016\/j.bioorg.2026.109609_bb0235","series-title":"Tead targeting compounds and methods thereof","author":"Agency for Science, Technology and Research","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_bb0240","series-title":"Carboxamide and sulfonamide derivatives useful as tead modulators","author":"Genentech","year":"2020"},{"key":"10.1016\/j.bioorg.2026.109609_bb0245","series-title":"Bicyclic compounds as tead inhibitor","author":"Dong-A","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_bb0250","series-title":"Yap\/taz-tead oncoproteins inhibitors","author":"Bridgene Biosciences","year":"2023"},{"key":"10.1016\/j.bioorg.2026.109609_rf0220","doi-asserted-by":"crossref","first-page":"9206","DOI":"10.1021\/acs.jmedchem.2c00403","article-title":"Optimization of TEAD P-site binding fragment hit into in vivo active lead MSC-4106","volume":"65","author":"Heinrich","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109609_rf0225","series-title":"Tricyclic heterocycles useful as tead binders","author":"Merck","year":"2021"},{"key":"10.1016\/j.bioorg.2026.109609_or0070","unstructured":"Merck. 2,8-dihydropyrazolo[3,4-b]indole derivatives for use in the treatment of cancer. WO2022233442; 2022."},{"key":"10.1016\/j.bioorg.2026.109609_bb0260","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1021\/acs.jmedchem.4c01949","article-title":"MoA studies of the TEAD P-site binding ligand MSC-4106 and its optimization to TEAD1-selective amide M3686","volume":"68","author":"Heinrich","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109609_bb0265","doi-asserted-by":"crossref","unstructured":"a) Insilico Medicine. Tead inhibitors and methods of uses thereof. WO2024067773; 2024. b) Qi Li,\u202fJainfei Wan,\u202fJinxin Liu,\u202fJing Shang,\u202fJiaojiao Yu,\u202fWei Zhu,\u202fCelia X.-J. Chen,\u202fJunwen Qiao,\u202fLing Wang,\u202fMan Zhang,\u202fXiao Ding,\u202fSupriya Bavadekar,\u202fSujata Rao,\u202fFeng Ren,\u202fAlex Zhavoronkov; Abstract 1656: ISM6331, a novel and potent pan-TEAD inhibitor, exhibits strong anti-tumor activity in preclinical models of Hippo pathway-dysregulated cancers.\u202fCancer Res\u202f15 March 2024; 84 (6_Supplement): 1656.\u202fhttps:\/\/doi.org\/10.1158\/1538-7445.AM2024-1656 c) Insilico Medicine. Crystalline TEAD Inhibitor and Uses Thereof. WO2025209524; 2025. d) Insilico Medicine. TEAD inhibitor combinations and uses thereof. WO2025190406; 2025.","DOI":"10.1158\/1538-7445.AM2024-1656"},{"key":"10.1016\/j.bioorg.2026.109609_bb0270","doi-asserted-by":"crossref","unstructured":"a) Hagenbeek, T.J., Zbieg, J.R., Hafner, M.\u202fet al.\u202fAn allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance.\u202fNat Cancer\u202f4, 812\u2013828 (2023). https:\/\/doi.org\/10.1038\/s43018-023-00577-0. b) Genentech. Therapeutic compounds. WO2019232216; 2019. c) Genentech. Therapeutic compounds. WO2021108483; 2021. d) https:\/\/acs.digitellinc.com\/p\/s\/discovery-of-gne-7883-a-novel-reversible-pan-tead-binder-which-functions-as-an-allosteric-inhibitor-against-yaptaz-hit-identification-rational-design-and-in-vivo-pkpd-results-41592.","DOI":"10.1038\/s43018-023-00577-0"},{"key":"10.1016\/j.bioorg.2026.109609_bb0275","unstructured":"Vivace Therapeutics. Benzocarbonyl compounds. WO2019113236; 2019."},{"key":"10.1016\/j.bioorg.2026.109609_bb0280","unstructured":"Vivace Therapeutics. Benzosulfonyl compounds. WO2019040380; 2019."},{"key":"10.1016\/j.bioorg.2026.109609_bb0285","unstructured":"Likang. Heterocyclic Compounds for TEAD Inhibitors. CN115466243A; 2022."},{"key":"10.1016\/j.bioorg.2026.109609_bb0290","unstructured":"Likang. Tead Inhibitor. WO2023280254; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0295","unstructured":"Vivace Therapeutics. Phenyl phosphine oxide compounds and methods of use thereof. WO2023204822; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0300","unstructured":"Sporos Biodiscovery. Tead inhibitors and methods of use. WO2024020350; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0305","unstructured":"Bayer. Tead Inhibitors. WO2024003259; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0310","unstructured":"Merck. Aryl ether compounds as tead modulators. WO2022177869; 2022."},{"key":"10.1016\/j.bioorg.2026.109609_or0125","unstructured":"a) Suzhou Genhouse Bio. Phosphorus-containing compound, pharmaceutical composition and use thereof. WO2024088398; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_or0130","unstructured":"b) Suzhou Genhouse Bio. Phosphorus-containing compound, pharmaceutical composition and use thereof. WO2024088399; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_or0135","unstructured":"c) Suzhou Genhouse Bio. Phosphorus-containing compound, pharmaceutical composition and use thereof. WO2024088400; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0320","unstructured":"Vivace Therapeutics. Non-fused tricyclic compounds. WO2018204532; 2018."},{"key":"10.1016\/j.bioorg.2026.109609_bb0325","unstructured":"Vivace Therapeutics. Oxadiazole compounds. WO2019222431; 2019."},{"key":"10.1016\/j.bioorg.2026.109609_bb0330","unstructured":"Vivace Therapeutics. Heteroaryl compounds. WO2021102204; 2021."},{"key":"10.1016\/j.bioorg.2026.109609_bb0335","unstructured":"Zeno Management. Azole compounds. WO2023049199; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0340","unstructured":"Likang. Heterocyclic compound as tead inhibitor. WO2023116877; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0345","unstructured":"Basilea Pharmaceutica. 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer. WO2021018869; 2021."},{"key":"10.1016\/j.bioorg.2026.109609_bb0350","unstructured":"Basilea Pharmaceutica. 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer. WO2023057371; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0355","unstructured":"Signet Therapeutics. Tricyclic compounds and application thereof. WO2023143354; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0360","unstructured":"Vivace Therapeutics. Compounds and methods of use thereof. WO2023146511; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0365","unstructured":"Vivace Therapeutics. Compounds and methods of use thereof. WO2023146513; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0370","unstructured":"Vivace Therapeutics. Compounds and methods of use thereof. WO2023146512; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0375","unstructured":"Orion Corporation. Tead inhibitors. WO2022219246; 2022."},{"key":"10.1016\/j.bioorg.2026.109609_bb0380","unstructured":"The general hospital Corp. Novel small molecule inhibitors of tead transcription factors. WO2020190774; 2020."},{"key":"10.1016\/j.bioorg.2026.109609_bb0385","unstructured":"Yonsei University. Novel 2-(phenylamino)pyridine-based tead inhibitor and pharmaceutical composition comprising them. WO2023167516; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0390","unstructured":"a) Vivace Therapeutics. Bicyclic compounds. WO2020214734; 2020. b) Vivace Therapeutics. Compounds and Methods for Treating Cancer. WO2025034563; 2025. c) Vivace Therapeutics. Combination therapy. WO2025122956; 2025. Please refer to refs.135c\u2013e for more information on compound (I)."},{"key":"10.1016\/j.bioorg.2026.109609_bb0395","unstructured":"Vivace Therapeutics. Tertiary carboxamide compounds. WO2022087008; 2022."},{"key":"10.1016\/j.bioorg.2026.109609_bb0400","unstructured":"Opna Bio SA. Compounds and methods for yap\/tead modulation and indications thereof. WO2023147063; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0405","unstructured":"Opna Bio. Compounds and methods for yap\/tead modulation and indications thereof. WO2024159067; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0410","unstructured":"Opna Bio. Compounds and methods for yap\/tead modulation and indications thereof. WO2024159079; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0415","unstructured":"Opna Bio. Compounds and methods for yap\/tead modulation and indications thereof. WO2024159081; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0420","unstructured":"Opna Bio. Compounds and methods for yap\/tead modulation and indications thereof. WO2024159088; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0425","unstructured":"Opna Bio. Compounds and methods for yap\/tead modulation and indications thereof. WO2024159103; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0430","unstructured":"Hanmi Pharm. Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same. WO2024080792; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0435","unstructured":"Jiangsu Hengrui. Indazole compound, preparation method therefor, and use thereof in medicine. WO2023186058; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0440","unstructured":"Springworks Therapeutics. Indoles, indazoles, and related analogs for inhibiting yap\/taz-tead. WO2023122782; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0445","unstructured":"Signet Therapeutics. Heteroaromatic compounds and uses thereof. CN118420607; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0450","unstructured":"Merck. Tricyclic Heterocycles. WO2022018072; 2022."},{"key":"10.1016\/j.bioorg.2026.109609_bb0455","unstructured":"Merck. Tricyclic Heterocycles. WO2023072974; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0460","unstructured":"Deuracor. Polycyclic compound and use thereof. WO2023016562; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0465","unstructured":"Etern Biopharma. Bicyclic heteroaryl compounds and uses thereof. WO2023151560; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0470","unstructured":"Springworks Therapeutics. Tetrahydrobenzoazepinones and related analogs for inhibiting yap\/taz-tead. WO2023122781; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0475","unstructured":"Springworks Therapeutics. Spiros and related analogs for inhibiting yap\/taz-tead. WO2023122784; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0480","unstructured":"Springworks Therapeutics. Dihydroquinazolinones and related analogs for inhibiting yap\/taz-tead. WO2023164596; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0485","unstructured":"Ikena Oncology. Tead inhibitors and uses thereof. WO2020243415; 2020."},{"key":"10.1016\/j.bioorg.2026.109609_bb0490","unstructured":"a) Ikena Oncology. Tead inhibitors and uses thereof. WO2023060227; 2023. b) Ikena Oncology. Tead inhibitors and uses thereof. WO2023114984; 2023. c) Ikena Oncology. Polymorphic compounds and uses thereof. WO2023211889; 2023. d) Ikena Oncology. Tead inhibitors and uses thereof. WO2020243415; 2020."},{"key":"10.1016\/j.bioorg.2026.109609_bb0495","unstructured":"Ikena Oncology. Tead inhibitors and uses thereof. WO2022120353; 2022."},{"key":"10.1016\/j.bioorg.2026.109609_bb0500","unstructured":"Likang. Tead Inhibitors. WO2024099435; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0505","unstructured":"Phecda Med. Small molecular compound with phosphoryl aryl structure and application thereof. CN117756855; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0510","unstructured":"Astrazeneca. Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer. WO2023209084; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0515","unstructured":"Astrazeneca. Bicyclic heteroaromatic compounds and their application in the treatment of cancer. WO2023209090; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0520","unstructured":"The General Hospital Corp. Small molecule inhibitors of tead-yap. WO2023049808; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0525","unstructured":"Vivace Therapeutics. Bicyclic compounds. WO2020097389; 2020."},{"key":"10.1016\/j.bioorg.2026.109609_bb0530","unstructured":"Cedilla Therapeutics. Tead inhibitors and uses thereof. WO2022272036; 2022."},{"key":"10.1016\/j.bioorg.2026.109609_bb0535","unstructured":"Sporos Biodiscovery. Tead inhibitors and methods of use. WO2023183437; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0540","unstructured":"Springworks Therapeutics. Tetrahydropyridopyrimidines and related analogs for inhibiting yap\/taz-tead. WO2023150619; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_or0365","unstructured":"a) Baobab AIBio. Heterobicyclic compound and pharmaceutical composition comprising them. WO2024210578; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_or0370","unstructured":"b) please see reference 18a."},{"key":"10.1016\/j.bioorg.2026.109609_bb0550","unstructured":"Cedilla Therapeutics. Tead inhibitors and uses thereof. WO2022204452; 2022."},{"key":"10.1016\/j.bioorg.2026.109609_bb0555","unstructured":"Signet Therapeutics. Compound and Medical Application Thereof. CN116535379A; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0560","unstructured":"Deuracor. Polycyclic compound and use thereof. WO2023134692; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0565","unstructured":"Vivace Therapeutics. Tricyclic compounds. WO2017058716; 2017."},{"key":"10.1016\/j.bioorg.2026.109609_or0395","unstructured":"Novartis. Biaryl derivatives as yap\/taz-tead protein-protein interaction inhibitors. WO2021186324; 2021."},{"key":"10.1016\/j.bioorg.2026.109609_or0400","unstructured":"Novartis. Crystalline forms of a biaryl yap\/taz-tead protein-protein interaction inhibitor. WO2024176128; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_rf0235","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1021\/acs.jcim.3c00122","volume":"63","author":"Awoonor-Williams","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2026.109609_rf0240","volume":"17","author":"Furet","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.109609_rf0245","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300051","volume":"18","author":"Sellner","year":"2023","journal-title":"ChemMedChem"},{"issue":"8_Supplement","key":"10.1016\/j.bioorg.2026.109609_rf0250","doi-asserted-by":"crossref","first-page":"LB319","DOI":"10.1158\/1538-7445.AM2023-LB319","article-title":"Abstract LB319: IAG933, a selective and orally efficacious YAP1\/WWTR1(TAZ)-pan TEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations","volume":"83","author":"Schmelzle","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109609_or0405","doi-asserted-by":"crossref","unstructured":"Chapeau, E.A., Sansregret, L., Galli, G.G. et al. Direct and selective pharmacological disruption of the YAP\u2013TEAD interface by IAG933 inhibits hippo-dependent and RAS\u2013MAPK-altered cancers. Nat. Cancer 5, 1102\u20131120 (2024). doi:https:\/\/doi.org\/10.1038\/s43018-024-00754-9 h) https:\/\/www.oncologypipeline.com\/apexonco\/novartis-trips-over-hippo.","DOI":"10.1038\/s43018-024-00754-9"},{"key":"10.1016\/j.bioorg.2026.109609_or0410","unstructured":"https:\/\/www.oncologypipeline.com\/apexonco\/novartis-trips-over-hippo."},{"key":"10.1016\/j.bioorg.2026.109609_or0415","unstructured":"919O A first-in-human study of oral IAG933 in adult patients with advanced mesothelioma and other solid tumours. Garralda, E. et al. Ann. Oncol., 36, S600."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109609_rf0255","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1535-7163.MCT-23-0371","article-title":"Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation\u2013positive lung cancer","volume":"23","author":"Tatsuya Ogimoto","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109609_rf0260","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1380584","article-title":"KRAS G12C inhibitor combination therapies: current evidence and challenge","volume":"14","author":"Miyashita","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109609_rf0265","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-025-02473-8","article-title":"Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges","volume":"10","author":"Choucair","year":"2025","journal-title":"Sig. Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.109609_rf0270","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26167910","article-title":"BRAF V600E mutation has variable tumor-specific effects on expression of MAPK pathway genes that could affect patient outcome","volume":"26","author":"Darabi","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109609_bb0575","unstructured":"Etern BioPharma. Tricyclic compound, preparation therefor, pharmaceutical composition and use. WO2023137634; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0580","unstructured":"Etern BioPharma. Inhibitor of interaction between yap\/taz and tead, preparation thereof, pharmaceutical composition thereof and use thereof. WO2023155927; 2023."},{"issue":"7_Supplement","key":"10.1016\/j.bioorg.2026.109609_bb0585","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-1671","article-title":"Abstract 1671: discovery of ETS-003, a potent and selective YAP\/TAZ-TEAD PPI inhibitor with broad anti-tumor activity in hippo-YAP aberrant cancers","volume":"83","author":"Lu","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109609_bb0590","unstructured":"Shanghai Qizhen Pharmaceutical Technology. Aromatic compound, pharmaceutical composition and application thereof. CN116217554; 2022."},{"issue":"13","key":"10.1016\/j.bioorg.2026.109609_bb0595","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109609_bb0600","doi-asserted-by":"crossref","unstructured":"Chen, Hui et al. Heliyon, Volume 10, Issue 18, e37829. Targeted degradation of specific TEAD paralogs by small molecule degraders.","DOI":"10.1016\/j.heliyon.2024.e37829"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109609_bb0605","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/acsmedchemlett.4c00029","volume":"15","author":"Li","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109609_rf0290","volume":"62","author":"Ji","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109609_rf0295","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/2472555220979584","article-title":"Target validation using PROTACs: applying the four pillars framework","volume":"26","author":"Nowak","year":"2021","journal-title":"SLAS Discov."},{"key":"10.1016\/j.bioorg.2026.109609_or0440","doi-asserted-by":"crossref","unstructured":"c) Nguyen, T.M., Sreekanth, V., Deb, A. et al. Proteolysis-targeting chimeras with reduced off-targets. Nat. Chem. 16, 218\u2013228 (2024). doi:https:\/\/doi.org\/10.1038\/s41557-023-01379-8.","DOI":"10.1038\/s41557-023-01379-8"},{"key":"10.1016\/j.bioorg.2026.109609_bb0615","doi-asserted-by":"crossref","unstructured":"a) L. Cao,\u202fJ. Yang,\u202fY. Liu, et al. \u201c\u202fDiscovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity.\u201d\u202fAdv. Sci.\u202f12, no.\u202f48\u202f(2025): e03277.\u202fhttps:\/\/doi.org\/10.1002\/advs.202503277. b) Kehao Zhao,\u202fWenchao Lu,\u202fLinghui Cao,\u202fYuhang Liu,\u202fYufang Shi,\u202fJian Chen,\u202fYong Zhang; Abstract LB438: Discovery of a potent and selective pan-TEAD PROTAC directly targeting TEAD-YAP interaction with durable degradation activity.\u202fCancer Res\u202f15 April 2025; 85 (8_Supplement_2): LB438.\u202fhttps:\/\/doi.org\/10.1158\/1538-7445.AM2025-LB438.","DOI":"10.1158\/1538-7445.AM2025-LB438"},{"key":"10.1016\/j.bioorg.2026.109609_bb0620","doi-asserted-by":"crossref","unstructured":"Lu, Y. et al. J. Med. Chem. 2025, 68, 5, 5616\u20135640.","DOI":"10.1021\/acs.jmedchem.4c02884"},{"key":"10.1016\/j.bioorg.2026.109609_bb0625","unstructured":"Novartis AG. Bifunctional Degraders Comprising a TEAD Binder. WO2023031801; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0630","unstructured":"The Board of Trustees of the Leland Stanford Junior University. Transcriptional Enhanced Associate Domain (TEAD) Degraders and Uses Thereof. WO2023154811; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0635","unstructured":"Merck Patent GMBH. Heterofunctional Molecules as TEAD Inhibitors. WO2023078813; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0640","unstructured":"Genentech, Inc. Heterofunctional Molecules as TEAD Inhibitors. WO2021178339; 2021."},{"key":"10.1016\/j.bioorg.2026.109609_bb0645","unstructured":"Zhongshan hospital Fudan University. Application of TEAD1 inhibitor in preparation of heart failure resistant medicines. CN116077510; 2023."},{"key":"10.1016\/j.bioorg.2026.109609_bb0650","doi-asserted-by":"crossref","unstructured":"Liang, H., Xu, Y., Zhao, J. et al. Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers. Cancer Gene Ther. (2024). doi:https:\/\/doi.org\/10.1038\/s41417-024-00761-z.","DOI":"10.1038\/s41417-024-00761-z"},{"key":"10.1016\/j.bioorg.2026.109609_or0485","doi-asserted-by":"crossref","unstructured":"a) Hagenbeek, T.J., Zbieg, J.R., Hafner, M. et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nat. Cancer 4, 812\u2013828 (2023). doi:https:\/\/doi.org\/10.1038\/s43018-023-00577-0.","DOI":"10.1038\/s43018-023-00577-0"},{"key":"10.1016\/j.bioorg.2026.109609_or0490","doi-asserted-by":"crossref","unstructured":"b) Kapoor, A. et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158, 185\u2013197 (2014).","DOI":"10.1016\/j.cell.2014.06.003"},{"key":"10.1016\/j.bioorg.2026.109609_or0495","doi-asserted-by":"crossref","unstructured":"c) Shao, D. D. et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171\u2013184 (2014).","DOI":"10.1016\/j.cell.2014.06.004"},{"key":"#cr-split#-10.1016\/j.bioorg.2026.109609_bb0660.1","doi-asserted-by":"crossref","unstructured":"a) Ko B, Paucar D, Halmos B.\u202fEGFR\u202fT790M: revealing the secrets of a gatekeeper. Lung Cancer (Auckl). 2017 Oct 9;8:147-159. doi: 10.2147\/LCTT.S117944. PMID: 29070957","DOI":"10.2147\/LCTT.S117944"},{"key":"#cr-split#-10.1016\/j.bioorg.2026.109609_bb0660.2","doi-asserted-by":"crossref","unstructured":"2024. d) Charitou, T., Srihari, S., Lynn, M.A.\u202fet al.\u202fTranscriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS G13D\u202fmutation.\u202fBr J Cancer\u202f121, 37-50 (2019). https:\/\/doi.org\/10.1038\/s41416-019-0477-7. e) M. Acunzo, G. Romano, G. Nigita, D. Veneziano, L. Fattore, A. Lagan\u00e0, N. Zanesi, P. Fadda, M. Fassan, L. Rizzotto, R. Kladney, V. Coppola, & C.M. Croce, Selective targeting of point-mutated KRAS through artificial microRNAs, Proc. Natl. Acad. Sci. U.S.A. 114 (21) E4203-E4212, https:\/\/doi.org\/10.1073\/pnas.1620562114 (2017).","DOI":"10.1073\/pnas.1620562114"},{"key":"#cr-split#-10.1016\/j.bioorg.2026.109609_bb0660.3","unstructured":"a) Ko B, Paucar D, Halmos B.\u202fEGFR\u202fT790M: revealing the secrets of a gatekeeper. Lung Cancer (Auckl). 2017 Oct 9;8:147-159. doi: 10.2147\/LCTT.S117944. PMID: 29070957; PMCID: PMC5640399. b) Ikena Oncology. Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and\/or mek inhibitor for use in the treatment of lung cancer. WO2022159986; 2022. c) Ikena Oncology. Combination of tead inhibitors and egfr inhibitors and uses thereof. WO2024092116; 2024. d) Charitou, T., Srihari, S., Lynn, M.A.\u202fet al.\u202fTranscriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS G13D\u202fmutation.\u202fBr J Cancer\u202f121, 37-50 (2019). https:\/\/doi.org\/10.1038\/s41416-019-0477-7. e) M. Acunzo, G. Romano, G. Nigita, D. Veneziano, L. Fattore, A. Lagan\u00e0, N. Zanesi, P. Fadda, M. Fassan, L. Rizzotto, R. Kladney, V. Coppola, & C.M. Croce, Selective targeting of point-mutated KRAS through artificial microRNAs, Proc. Natl. Acad. Sci. U.S.A. 114"},{"key":"#cr-split#-10.1016\/j.bioorg.2026.109609_bb0660.4","doi-asserted-by":"crossref","unstructured":"(21) E4203-E4212, https:\/\/doi.org\/10.1073\/pnas.1620562114 (2017).","DOI":"10.1073\/pnas.1620562114"},{"key":"10.1016\/j.bioorg.2026.109609_bb0665","unstructured":"Ikena Oncology. Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and\/or mek inhibitor for use in the treatment of lung cancer. WO2024173761; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0670","unstructured":"Novartis. Tead- and her2-inhibitor combinations for treating cancer. WO2024176130; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0675","unstructured":"Novartis. Tead- and kras g12d-inhibitor combinations for treating cancer. WO2024176131; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_bb0680","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1692512","article-title":"Targeting TEAD in cancer","volume":"15","author":"Battina","year":"2025","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109609_bb0685","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.1021\/acs.jmedchem.2c00075","volume":"65","author":"Gibault","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109609_bb0690","unstructured":"Ikena Oncology. TEAD inhibitors and uses thereof in the treatment of proliferative disorders. WO2024220470; 2024."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109609_bb0695","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.trecan.2024.10.004","article-title":"Targeting the hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?","volume":"11","author":"Paul","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bioorg.2026.109609_rf0315","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1128\/MCB.26.1.77-87.2006","article-title":"Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of YAP65","volume":"26","author":"Morin-Kensicki","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bioorg.2026.109609_rf0320","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119640","article-title":"Routes of albumin overload toxicity in renal tubular epithelial cells","volume":"24","author":"Eleftheriadis","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109609_rf0325","doi-asserted-by":"crossref","first-page":"D1038","DOI":"10.1093\/nar\/gkac972","article-title":"The international mouse phenotyping consortium: comprehensive knockout phenotyping underpinning the study of human disease","volume":"51","author":"Groza","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.109609_rf0330","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219699120","article-title":"A single-cell multiomic analysis of kidney organoid differentiation","volume":"120","author":"Yoshimura","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2026.109609_rf0335","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1128\/MCB.26.1.77-87.2006","article-title":"Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of YAP65","volume":"26","author":"Morin-Kensicki","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bioorg.2026.109609_rf0340","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1073\/pnas.0605266104","article-title":"Glomerulocystic kidney disease in mice with a targeted inactivation of WWTR1","volume":"104","author":"Hossain","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2026.109609_rf0345","doi-asserted-by":"crossref","first-page":"F542","DOI":"10.1152\/ajprenal.00201.2007","article-title":"Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ","volume":"294","author":"Makita","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.bioorg.2026.109609_rf0350","doi-asserted-by":"crossref","first-page":"F419","DOI":"10.1152\/ajprenal.00426.2021","article-title":"TAZ is important for maintenance of the integrity of podocytes","volume":"322","author":"Chen","year":"2022","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"11, Supplement","key":"10.1016\/j.bioorg.2026.109609_rf0355","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/j.jtho.2023.09.680","article-title":"P2.19\u201301 First-in-human phase 1 trial of VT3989, a first-in-class YAP\/TEAD inhibitor in patients with advanced mesothelioma","volume":"18","author":"Yap","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2026.109609_or0525","doi-asserted-by":"crossref","unstructured":"Yap, T.A., Kwiatkowski, D.J., Dagogo-Jack, I. et al. YAP\/TEAD inhibitor VT3989 in solid tumors: a phase 1\/2 trial. Nat. Med. 31, 4281\u20134290 (2025). doi:https:\/\/doi.org\/10.1038\/s41591-025-04029-3.","DOI":"10.1038\/s41591-025-04029-3"},{"key":"10.1016\/j.bioorg.2026.109609_or0530","unstructured":"Vivace Therapeutics. Synthesis of a naphthalenecarboxmaide as hippo-YAP pathway modulator and a polymorph thereof. WO2024206300; 2024."},{"key":"10.1016\/j.bioorg.2026.109609_or0535","unstructured":"Vivace Therapeutics. Preparation of amino acid (R)-2-[5-[4-(trifluoromethyl)phenoxy]-2-naphthamido]propyl esters and related compounds for modulating YAP-TEAD\/hippo pathway. WO2025101655; 2025."},{"key":"10.1016\/j.bioorg.2026.109609_or0540","unstructured":"Vivace Therapeutics. Pharmaceutical formulation in solid dosage form for treating cancer and dosing schedules of Hippo-YAP pathway modulator. WO2024216121; 2024. Note: The structure in compound (I) in the TOC graphic is assigned as the most probable identity of VT3989 based on the convergence of synthetic disclosure, optimized polymorphs, salt forms and formulation in references 142c\u2013e above."},{"key":"10.1016\/j.bioorg.2026.109609_bb0715","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62857","article-title":"TAZ-CAMTA1 and YAP-TFE3 alter the TAZ\/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex","volume":"10","author":"Merritt","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.bioorg.2026.109609_rf0365","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3168","article-title":"A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors","volume":"40","author":"Tolcher","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109609_or0545","unstructured":"https:\/\/www.biospace.com\/ikena-oncology-shares-initial-positive-and-differentiated-dose-escalation-data-from-ik-930-phase-i-trial-and-reports-third-quarter-2023-financial-results."},{"key":"10.1016\/j.bioorg.2026.109609_or0550","doi-asserted-by":"crossref","unstructured":"Nathan Young, George Punkosdy, Jill Cavanaugh, Collin Bantle, Alex Constan, Bin Li, James Conley, Marta Sanchez-Martin, Lan Xu, Karen McGovern, Alfredo Castro, Michelle Zhang, Jeffrey Ecsedy; Abstract 1646: IK-930, a paralog-selective TEAD inhibitor for treating YAP\/TAZ-TEAD dependent cancers. Cancer Res. 2023; 83 (7_Supplement): 1646. doi:https:\/\/doi.org\/10.1158\/1538-7445.AM2023-1646.","DOI":"10.1158\/1538-7445.AM2023-1646"},{"key":"10.1016\/j.bioorg.2026.109609_or0555","doi-asserted-by":"crossref","unstructured":"Liu X, Zhong D, Tang C, et al. In vitro and in vivo drug metabolism analysis of BPI-460372 - a covalent TEAD1\/3\/4 inhibitor. Curr. Drug Metab. 2024;25(10):754\u2013768. doi:https:\/\/doi.org\/10.2174\/0113892002351556250123105344.","DOI":"10.2174\/0113892002351556250123105344"},{"issue":"6_Supplement","key":"10.1016\/j.bioorg.2026.109609_rf0370","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-7575","article-title":"Abstract 7575: BPI-460372, a covalent, irreversible TEAD inhibitor in phase I clinical development","volume":"84","author":"Han","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109609_bb0730","doi-asserted-by":"crossref","unstructured":"Pham, T. H. et al. Machine-learning and chemicogenomics approach defines and predicts cross-talk of hippo and MAPK pathways. Cancer Discov. 11, 778\u2013793 (2021).","DOI":"10.1158\/2159-8290.CD-20-0706"},{"key":"10.1016\/j.bioorg.2026.109609_bb0735","doi-asserted-by":"crossref","unstructured":"Paul, S., Hagenbeek, T.J., Tremblay, J. et al. Cooperation between the hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition. Nat. Commun. 16, 1743 (2025). doi:https:\/\/doi.org\/10.1038\/s41467-025-56634-y.","DOI":"10.1038\/s41467-025-56634-y"},{"key":"10.1016\/j.bioorg.2026.109609_bb0740","doi-asserted-by":"crossref","unstructured":"Jiang, X. et al. Expression and function of FRA1 protein in tumors. Mol. Biol. Rep. 47, 737\u2013752 (2020).","DOI":"10.1007\/s11033-019-05123-9"},{"key":"10.1016\/j.bioorg.2026.109609_rf0375","doi-asserted-by":"crossref","DOI":"10.3390\/cells13070564","article-title":"Hippo signaling at the hallmarks of cancer and drug resistance","volume":"13","author":"Kumar","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.109609_or0575","doi-asserted-by":"crossref","unstructured":"Liu, Y., et al. (2016). Increased TEAD4 expression and nuclear localization in colorectal cancer promotes epithelial-mesenchymal transition and metastasis in a YAP-independent manner. Oncogene, 35(21), 2789\u20132800. doi:https:\/\/doi.org\/10.1038\/onc.2015.342.","DOI":"10.1038\/onc.2015.342"},{"key":"10.1016\/j.bioorg.2026.109609_bb0750","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fcell.2019.00156","article-title":"Safety considerations in the development of hippo pathway inhibitors in cancers","volume":"7","author":"Kakiuchi-Kiyota","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2026.109609_bb0755","doi-asserted-by":"crossref","unstructured":"Totaro, A. et al. (2018) YAP\/TAZ upstream signals and down- stream responses. Nat. Cell Biol. 20, 888\u2013899.","DOI":"10.1038\/s41556-018-0142-z"},{"key":"10.1016\/j.bioorg.2026.109609_bb0760","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","article-title":"Targeting the hippo pathway in cancer, fibrosis, wound healing and regenerative medicine","volume":"19","author":"Dey","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109609_bb0765","doi-asserted-by":"crossref","unstructured":"Yu Y et al. Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases. Pharmacol. Res. 2020;159:105009. doi:https:\/\/doi.org\/10.1016\/j.phrs.2020.105009. Epub 2020 Jun 15. PMID: 32553712.","DOI":"10.1016\/j.phrs.2020.105009"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826001458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826001458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:53:47Z","timestamp":1772891627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826001458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":197,"alternative-id":["S0045206826001458"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109609","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Multi-Faceted Landscape of TEAD Inhibition: a 2017\u20132025 Patent and Literature Review","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109609"}}